Virtual Event | September 26, 2023

Stability To Scalability: The Future Of Viral Vector Therapies

Several advances have already contributed to improvements in viral vector yields. Yet, the CGT sector is still in need of innovations in all aspects of the process to impact product quality. During this Cell & Gene Live webinar, Chief Editor, Erin Harris welcomed Dave Maheu, Vice President, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO for a discussion on accelerating scale for viral vector production. Available on-demand thanks to the support of Thermo Fisher Scientific.

access the Virtual Event!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Thermo Fisher Scientific Bioproduction